Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
opnt003 save search
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
Published: 2023-01-19 (Crawled : 00:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
opnt003 fda pharmaceuticals opioid review
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -3.87%
H: 3.16%
C: 0.67%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -2.41%
H: 0.51%
C: -0.9%
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: -1.51%
H: 8.43%
C: -1.53%
opnt002 alcohol pharmaceuticals trial phase 2
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
Published: 2022-08-22 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.54%
H: 1.57%
C: 1.57%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: -8.63%
H: 4.42%
C: 2.81%
opnt004 treatment patent
Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
Published: 2022-06-01 (Crawled : 22:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: 0.74%
H: 2.49%
C: 2.42%
opnt003 treatment drug opioid application food submission
Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone
Published: 2022-04-27 (Crawled : 21:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: 0.25%
H: 0.96%
C: -2.77%
opnt003 topline positive results
Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene
Published: 2022-02-10 (Crawled : 14:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: 0.74%
H: 11.54%
C: 7.85%
opnt003 als positive
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
Published: 2022-01-24 (Crawled : 22:00) - biospace.com/
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: -3.08%
H: 7.12%
C: 4.99%
opnt003 als program contract funding
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
Published: 2022-01-20 (Crawled : 23:00) - globenewswire.com
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: -0.32%
H: 2.23%
C: 1.99%
opnt002 alcohol use disorder phase 2 als order trial trex
Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
Published: 2021-02-08 (Crawled : 21:03) - globenewswire.com
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: 1.56%
H: 7.69%
C: 3.51%
treatment opioid
Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
Published: 2020-12-14 (Crawled : 21:05) - globenewswire.com
OPNT | $20.65 -0.58% 0.48% 0
|
Health Technology
|
| O: 10.63%
H: 6.72%
C: -8.64%
contract program
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.